Introduction
Arterial thrombus formation is a key event in myocardial infarction and stroke. 1 Indeed, after plaque rupture or erosion in culprit coronary arteries as it occurs in acute coronary syndromes (ACS), 2 local platelet adhesion and fibrin formation ensues eventually leading to distal embolism of thrombotic material and/or complete vascular occlusion at the site of vascular injury. 3 Similarly, in the absence of appropriate antiplatelet and antithrombotic therapy, balloon angioplasty and/or stenting may lead to coronary or carotid occlusion due to the local vascular injury induced by the procedure. 4 The degree of arterial thrombus formation is determined by (1) the size of the injury (i.e. the larger the exposure of subendothelial structures and proteins, the more pronounced the thrombus formation), (2) the local flow conditions and, importantly (3) the expression level of procoagulant proteins, most importantly tissue factor. [5] [6] [7] [8] In atherosclerotic plaques, many of these proteins are highly expressed and may contribute to or prevent thrombotic occlusion. 9, 10 Lectin-like oxLDL receptor-1 (LOX-1) mediates the endothelial uptake of oxidized low-density lipoprotein (oxLDL), a key meditator of atherosclerosis into the vessel wall 11 and it is highly expressed in plaques and also in ACS. 12, 13 Activation of LOX-1 is linked to a variety of signaling pathways affecting vascular function, coagulation, and the interaction of circulating blood cells with the vessel wall. However, the role of LOX-1 in thrombus formation, a crucial event in ACS, 14 is completely unknown.
We therefore hypothesized that LOX-1 receptor may be involved in arterial thrombus formation. As the LOX-1 receptor is undetectable in the endothelium under physiological conditions, we used transgenic mice with endothelial-specific overexpression of the LOX-1 receptor and studied arterial thrombus formation after carotid artery injury in vivo as well as the molecular pathways involved. Our findings for the first time demonstrate a dual role of the LOX-1 receptor in arterial thrombus formation and vascular occlusion depending on the oxLDL plasma levels.
Materials and methods
A detailed description of all materials and methods used in the present study is provided in the online Supplementary material.
All animal experiments conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health and was approved by local veterinary authority.
Mice
Endothelial-specific LOX-1TG mice were generated as previously described. 15 All animal experiments were performed on 12-to 14-week-old hemizygote LOX-1 transgenic and wild-type male mice. Both animal cohorts were littermates and were maintained on identical C57Bl/6 genetic background. All mice were maintained at 24 C with 12 h light/dark cycle and had free access to food and water. They were kept on a standard western type chow diet. All procedures were in accordance with the institutional guidelines for animal research and approved by the local animal committee.
Blood analyses
Mice were fasted over night before blood was drawn. Plasma and red cells were stored at -80 C. Total blood cell count was performed on a ScilVet ABCplus (Horiba, Kyoto, Japan) using EDTA-anticoagulated blood.
Bleeding times
Bleeding time was measured as described previously. 16 Briefly, mice were anesthetized by i.p. injection of sodium pentobarbital and the last 5 mm of the tail was cut with a razor. Tails were placed in saline at 37 C and the time to bleeding cessation was determined with a stopwatch.
OxLDL measurements
Oxidized low density lipoprotein (oxLDL) concentrations in mouse serum and carotid artery homogenates isolated from 12-to 14-weekold LOX-1TG and WT males was measured by a Mouse oxLDL ELISA Kit (Cusabio Biotech, Wuhan, P. R. China) according to the manufacturer's instructions.
In vivo carotid artery thrombosis model
LOX-1TG and corresponding WT males aged 12-14 weeks were anaesthetized by i.p. injection of 87 mg/kg sodium pentobarbital (Butler, Columbus, OH, USA). The depth of anesthesia was confirmed by the absence of twitch reflex. Rose Bengal (Fischer Scientific, Fair Lawn, NJ, USA) was diluted to 12 mg/mL in phosphate-buffered saline and then injected through the tail vein at a concentration of 63 mg/kg. Mice were placed in supine position under a dissecting microscope and the right common carotid artery was exposed by a midline cervical incision. A Doppler flow probe (Model 0.5 VB, Transonic Systems, Ithaca, NY, USA) was applied and connected to a flowmeter (Model T106, Transonic Systems, Ithaca, NY, USA). Five to ten min after Rose Bengal injection, a 1.5 mW green light laser (540 nm; Melles Griot, Carlsbad, CA, USA) was applied to the site of injury at a distance of 6 cm for 60 min or until thrombosis occurred. From the onset of injury, blood flow was monitored up to 120 min. 17 Occlusion was defined as blood flow below 0.1 mL/min for at least 1 min. After occlusion has occurred, the mouse was euthanized with i.p injection of 150 mg/kg sodium pentobarbital.
Tissue factor activity
Tissue factor surface activity in carotid artery extracts was measured by a colorimetric assay (American Diagnostica, Stamford, CT, USA). Right carotid arteries were homogenized in 50 lL of lysis buffer and let stand on ice for 30 min. Tissue extracts were incubated at 37 C with factors FVIIa and FX, allowing for the formation of the complex between TF and FVIIa. Conversion of FX to FXa was measured by the ability of FXa to cleave a chromogenic substrate. A standard curve was generated with lapidated human TF to assure a linear range of the detection.
NF-jB DNA-binding assay
Adhering murine aortic ECs isolated from LOX-1TG and WT mice were stimulated with 40 mg/mL oxLDL for 1, 6, and 24 h. Nuclear extracts were obtained by using a nuclear extraction kit (Active Motif, Carlsbad, CA, USA). The DNA binding reaction was carried out with 5 lg of nuclear protein in a 96-well plate coated with oligonucleotides (GGGACTTTCC) to consensus sequence for NF-jB (Active Motif, Carlsbad, CA, USA) for 1 h at RT. After washing, p65 antibody (Active Motif, Carlsbad, CA, USA) was added and incubated for 1 h followed by incubation with a horseradish peroxidase-conjugated secondary antibody. Finally, DNA-binding of p65 protein was assessed spectrophotometrically at 450 nm.
RT-PCR analysis
Quantitative real time PCR was performed using total RNA extracted from either murine carotid artery or aorta and the primers specific for S12, LOX-1, SIRT1, Oct-1, and p65 transcripts (see the Methods section in the Supplementary material online).
LOX-1 overexpression and arterial thrombosis
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assay was performed in carotid arteries isolated from WT and LOX-1TG mice after thrombosis as previously described. 18 A rabbit polyclonal antibody for octamer transcription factor 1 (Oct-1) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used for ChIP assay. Non-immune normal rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used as a control for immunoprecipitation. Precipitated genomic DNA was analysed by semiquantitative polymerase chain reaction using primers specific for the promoter regions of SIRT1, Oct-1, LOX-1, c-jun, and Hif1a genes. The primers were purchased from Microsynth AG (see Supplementary material online, Table S2 ).
In vivo injection of oxLDL
For in vivo experiments LOX-1TG males were intravenously injected with the single dose of human oxLDL (Biomedical Technologies Inc., Stoughton, MA, USA) at 15 mg/kg of mouse body weight in max. 150 lL, and 24 h later were applied for thrombosis model.
High cholesterol diet
Six-week-old male LOX-1TG mice were put on high-cholesterol diet (1.25% total cholesterol, D12108, Research Diets) for 6 weeks.
Statistical analysis
All data are presented as mean ± SEM. Statistical comparisons were made with the Student's t-test for unpaired data and 1-way ANOVA followed by the Bonferroni test when appropriate. Values of P < 0.05 were considered statistically significant. All analyses were performed with GraphPad Prism Software (version 5.0).
Results

Endothelial overexpression of LOX-1 in carotid arteries
Endothelium-specific transgenic mice (LOX-1TG) as described 15 were used to investigate the effects of LOX-1 on arterial thrombosis in the carotid artery following laser-induced photo-chemical injury. LOX-1TG mice showed marked LOX-1 overexpression in isolated carotid arteries as compared with WT littermates (see Supplementary material online, Figure S1 ).
Endothelial overexpression of LOX-1 attenuates arterial thrombosis
Unexpectedly, LOX-1TG fed a normal chow diet (ND) displayed prolonged occlusion times (36.9 ± 4.8 min, n = 10) compared to WT (22.7 ± 3.8 min; P < 0.05, Figure 1A and 1B), suggesting that endothelial LOX-1 overexpression protects against arterial thrombosis under these conditions. No significant difference in baseline blood flow was observed between both genotypes (WT, 0.6 ± 0.05 mL/min; LOX-1TG, 0.6 ± 0.04 mL/min, see Supplementary material online, Figure S2A ). Likewise, there was no difference in body weight, tail bleeding time, and platelet count between groups (see Supplementary material online, Figure S3 ). Similarly, in isolated platelets and P-selectin exposure and activation of the integrin IIb/IIIa did not differ between WT and LOX-1TG (16 ± 2 WT vs. 9.33 ± 1.2 LOX-1TG, P = 0.15 for P-selectin; 12.5 ± 0.5 WT vs. 8.7 ± 1.4 LOX-1TG, P = 0.2 for IIb/IIIa, n = 8 for each group).
LOX-1TG mice accumulate more oxLDL in carotid artery
Total cholesterol, triglycerides, high-density lipoprotein, and low-density lipoprotein plasma levels did not differ between LOX-1TG and WT mice after arterial thrombosis (Table 1) . However, in carotid artery homogenates of LOX-1TG oxLDL concentration were increased compared to WT (2.3 ± 0.4 vs. 1.5 ± 0.1 nmol/mL; P < 0.05), whereas oxLDL levels in plasma were comparable (3.4 ± 0.5 vs. 2.9 ± 0.3 nmol/mL).
Specific suppression of tissue factor signaling in LOX-1TG mice
In LOX-1TG, we observed a 50% reduction of TF surface activity as compared to WT ( Figure 1C) . The reduction of TF activity was associated with decreased TF mRNA expression (see Supplementary material on line, Figure S2B ). Moreover, immunohistochemistry showed that vascular TF expression was reduced in LOX-1TG as compared with WT mice (see Supplementary material online, Figure S4 ). However, no differences were found for prothrombin time, activated partial thromboplastin time measurements, and endogenous thrombin potential ( Table 2) .
Transcription factor Oct-1 is a critical intermediate between LOX-1 and SIRT1
Expression level of Oct-1, which is known to be upregulated by oxLDL through oxLDL/LOX-1 binding, was significantly increased both at the mRNA and protein level in carotid arteries of LOX-1TG mice as compared to WT (see Supplementary material online, Figure S5A and Figure 1D) .
We then performed in silico computer analysis of silent information regulator-two 1 (SIRT1) promoter sequence by searching for Oct-1 binding site(s) within 1000 bp promoter fragment (between nt -800 and þ200) retrieved from TRED database in the database TRANSFAC, which revealed multiple putative binding sites for Oct-1. Two sites located within 400 bp fragment (between nt -700 and -300) showed the highest binding probability. Next, we performed ChIP assay in carotid arteries isolated from LOX-1TG and WT mice and found that Oct-1 binds to the SIRT1 promoter in two regions (-663 bp to -478 and -590 bp to -350) ( Figure 2 ). This suggests that Oct-1 transcriptionally regulates SIRT1 in vessels of LOX-1TG mice.
3.6 SIRT1 upregulation abolishes NF-jB signaling in LOX-1TG mice SIRT1 expression was significantly increased both at the mRNA and protein level (see Supplementary material online, Figure S5B and Figure 1E ). Accordingly, SIRT1 upregulation in LOX-1TG mice was associated with reduced expression of Nuclear Factor (NF) kappa B subunit RelA/p65 (see Supplementary material online, Figure S5C and Figure 1F ). This latter finding contributed to the reduction of NF-jB-driven TF expression in LOX-1TG mice (see Supplementary material online, Figure S2B ).
3.7
In vivo knockdown of Oct-1 or SIRT1 blunts anti-thrombotic effect of LOX-1
Next, we performed in vivo knockdown of either Oct-1 or SIRT1 in LOX-1TG mice by i.v. administration of small interfering RNA (siRNA) via the tail vein in vivo. Time-course studies showed that vascular Oct-1 and SIRT1 expression was significantly downregulated 4 days after siRNA injection (see Supplementary material online, Figure S6A Figure S2C and S2E). Of note, enhanced thrombosis after inhibition of Oct-1/SIRT1 signaling was associated with a significant increase in TF surface activity ( Figures 3D and 4D ) and also mRNA expression of both isoforms of TF (see Supplementary material online, Figure S2D and S2F).
Silencing of Oct-1 suppressed SIRT1 mRNA, thus confirming that Oct-1 is required for SIRT1 upregulation ( Figure 3E ). As expected, Oct-1 mRNA was downregulated upon Oct-1 knockdown ( Figure 3F) . In contrast, Oct-1 mRNA expression was not affected by SIRT1 knockdown being still significantly higher compared to control (LOX-1TG injected with scrambled siRNA, Figure 4E ). Similar, there was no effect of SIRT1 knockdown on LOX-1 mRNA expression ( Figure 4F ).
In vivo injection of oxLDL is pro-thrombotic via the classical LOX-1 pathway
To explore whether the anti-thrombotic effect of LOX-1 is oxLDLdependent, we injected oxLDL in LOX-1TG mice i.v. ( Figure 5A ).
24 h later, mice were subjected to laser-induced photo-chemical injury.
In LOX-1TG mice, oxLDL injection resulted in a prothrombotic effect as reflected by a significant decrease in time to occlusion ( Figure 5B) . Again, initial blood flow was comparable in both groups ( Figure 5C ). Similar results were obtained on WT mice injected with the same dose of either oxLDL or PBS 24 h before photo-chemical injury (see Supplementary material online, Figure S7 ). Of note, oxLDL injection induced LOX-1 messenger RNA expression in WT mice (8.748e-006 ± 1.390e-006 vs. 3 .656e-006 ± 6.510e-007, P < 0.05, n = 4-5), whereas one for Oct-1 remained unchanged (0.00612 ± 0.001 vs. 0.004825 ± 0.001, n = 4-5).
3.9 Activation of LOX-1 by oxLDL induces the extracellular protein kinase ERK1/2
OxLDL administration led to an activation of the extracellular protein kinase ERK1/2 by increased phosphorylation ( Figure 5D, E) . Interestingly, we found that oxLDL was able to trigger arterial thrombosis by switching-off the protective Oct-1/SIRT1 pathway, as shown by a reduced mRNA expression of Oct-1 and a trend towards reduction of SIRT1 expression ( Figure 5F , G).
High cholesterol diet is prothrombotic via the classical LOX-1 pathway
To further investigate the prothrombotic effect of oxLDL, LOX-1TG mice were fed high cholesterol diet (HCD) for 6 weeks starting at 6 weeks of age followed by laser-induced photo-chemical injury ( Figure 6A) . At this stage, HCD does not induce atherosclerotic plaques in the carotid artery, but induces functional vascular changes. HCD led to increased thrombus formation as reflected by a decreased time to occlusion ( Figure 6B ) as well as to increased levels of oxLDL in plasma from LOX-1TG mice compared to WT (1.41 ± 0.1 vs. 1.04 ± 0.04 lmol/mL; P < 0.05) thus mimicking the injection of oxLDL in LOX-1TG mice. No significant difference in the initial blood flow was observed ( Figure 6C ). This accelerated thrombus formation was further associated with increased tissue factor total activity ( Figure 6D ). Of note, HCD also induced LOX-1 messenger RNA expression in wild type mice (see Supplementary material online, Figure S8 ).
High cholesterol diet induces the extracellular protein kinase ERK1/2
At the molecular level observed accelerated thrombus formation led again to an increased phosphorylation of ERK1/2, leaving however, expression of total ERK and Oct-1 unchanged ( Figure 6E-G Figure 2 Oct-1 positively regulates SIRT1 expression through direct binding to its promoter. ChIP assay on carotid arteries isolated from WT and LOX-1TG mice after in vivo thrombosis. Chromatin was immunoprecipitated with either normal rabbit IgG or antibody against Oct-1. Precipitated genomic DNA was then analysed by polymerase chain reaction using primers specific for SIRT1 (-663 bp to -478 and -590 bp to -350), Oct-1 (-944 bp to -672), LOX-1 (-298 bp to -178), c-jun (-586 bp to -338), and Hif1a (-83 bp to þ78) promoter regions. Figure S9 ).
High cholesterol diet increases oxLDL tissue levels in LOX-1TG mice
Finally, the tissue levels of oxLDL in carotid arteries of LOX-1TG mice fed HCD were significantly higher than those in carotid arteries of both WT and LOX-1TG mice fed a ND (13.3 ± 2.5 vs. 6 .3 ± 1.2 vs. 6.8 ± 1.1 nmol/ mL; P < 0.05; n = 5).
Discussion
We here show for the first time that activation of the LOX-1 receptor, which is involved in coronary artery disease and ACS, 19-21 plays a dual to (7) increased tissue factor activity and finally (8) enhanced thrombus formation and vascular occlusion in vivo. LOX-1 is a type II membrane glycoprotein that has a C-terminal extracellular C-type lectin-like domain, which is essential for binding of oxLDL. 22 Its expression levels are normally undetectable, but increased in hyperlipidemia, atherosclerosis, and in ACS at the site of coronary occlusion. 12, 19, 23 Thus, to study the role of LOX-1 in this context, activation of the receptor is required. We were able to specifically overexpress LOX-1 in the endothelium of mice leading to distinct functional changes, e.g. an increased oxLDL uptake into the intima. 15 Indeed, although baseline plasma levels of oxLDL did not differ between WT and LOX-1 transgenic mice, the vascular levels of the lipoprotein were significantly increased in the latter confirming that overexpressed LOX-1 was functionally active in vivo, i.e. binding and internalizing naturally occurring oxLDL from the blood stream. Surprisingly, in mice on a normal diet endothelial-specific LOX-1 overexpression, as confirmed previously by both immunostaining and bonemarrow transplantation experiments, 15 was associated with a markedly prolonged time to occlusion after laser injury of the carotid artery. In line with this observation vascular tissue factor expression and activity was reduced. This inhibition of tissue factor expression and activity observed in transgenic mice can be explained by the decrease in Nuclear Factor (NF) kappa B, a known regulator of TF expression. 6 This in turn is mediated by increased p65 subunit deacetylation caused by increased SIRT1 levels seen in transgenics. Of note the levels of other mediators regulating thrombus formation such as tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1, two important modulators of the fibrinolytic process, remained unchanged. 24, 25 Furthermore, platelet count and reactivity was also similar in WT and LOX-1TG mice. Thus, with normal lipid levels LOX-1 activation is associated with a specific suppression of vascular tissue factor expression and activity. Our findings were generated employing the well-established and highly reproducible rose bengal-induced laser injury model which is the most relevant arterial thrombosis model. Unlike alternative models such as the ferric chloride that lead to deep transmural lesions, 26, 27 laser injury induces an endothelium-specific lesion activating surrounding endothelial cells and exposing subendothelial structures and smooth muscle cells to the blood stream. The homeodomain transcription factor Oct-1 has been recognized to interact with LOX-1 in the human endothelium. 28, 29 Several studies have revealed that oxLDL treatment involves LOX-1/Oct-1 signal transduction mechanism upregulating Oct-1 mRNA and protein through oxLDL/ LOX-1 binding. [28] [29] [30] In addition, multiple Oct-1 binding motifs located within the Oct-1 transcriptional promoter suggest the existence of a positive feedback loop further upregulating Oct-1 expression in a LOX-1-dependent manner. 31, 32 . Indeed, we found an upregulation of this transcription factor in carotid arteries of LOX-1TG mice in vivo. 28, 33 We then investigated whether Oct-1 regulates SIRT1 transcription-a new downstream target of Oct-1 that has not been known yet. An in silico computer analysis of the SIRT1 promoter revealed multiple putative binding sites for Oct-1. Accordingly, Oct-1 bound to the SIRT1 promoter within two regions (-663 bp to -478 and -590 bp to -350). Using siRNA technology in vivo, we then demonstrated that silencing of Oct-1 transcriptionally downregulated SIRT1 in vessels of LOX-1TG mice showing that SIRT1 is a downstream affecter gene of Oct-1. Indeed, in LOX-1TG mice SIRT1 expression was increased both at mRNA and protein level and the expression of Nuclear Factor (NF) kappa B subunit RelA/p65 was reduced. Of note, transcription factor NFjB, especially its key catalytic subunit p65, is a well-known target of SIRT1, as has been shown in various recent publications. [34] [35] [36] [37] [38] To further delineate the molecular mechanism, we performed in vivo knockdown of either SIRT1 or Oct-1 in LOX-1TG mice by i.v. administration of siRNA via the tail vein. Interestingly, transient downregulation of both SIRT1 and Oct-1 significantly accelerated injury-induced carotid thrombus formation as compared with scrambled siRNA confirming their causal role in this process, particularly since enhanced thrombus formation and vascular occlusion were associated with an increased TF surface activity. As Oct-1 expression was not affected by genetic silencing of SIRT1, while silencing of Oct-1 suppressed SIRT1 mRNA, activation of the LOX-1 receptor leads to an activation of the transcription factor Oct-1 which in turn activates SIRT1 which then suppresses NF-jBdriven TF expression in LOX-1TG mice.
On the other hand, other regulators of coagulation such as PAI-1 and tPA as well as platelets counts and activation were not altered. Thus, although activation of the LOX-1 receptor impairs the activity of the endothelial L-arginine pathway, 15 this did not affect platelet reactivity in this setting. Finally, to investigate the role of LOX-1 during hyperlipidemia, in which oxLDL levels are elevated, 39 we first injected LOX-1 transgenic mice with oxLDL and then subjected them to laser-induced photochemical injury of the carotid artery. Under these conditions, thrombus formation was enhanced as reflected by reduced time to occlusion. At the molecular level this switch from a protective to a thrombogenic role of LOX-1 was related to activation of the 'classical' redox-sensitive ERK1/2/NFjB pathway inducing TF transcription and activity rather than the Oct-1/SIRT1 pathway. This thrombogenic effect could be confirmed in a further series of experiments in transgenic mice fed HCD in order to provide a chronic activation of LOX-1 by oxLDL, where again the ERK1/2/NFjB molecular pathway was activated. Similar effect on arterial thrombosis was observed in WT mice injected with recombinant oxLDL that also led to an increase in LOX-1 expression further strengthening the key role of LOX-1 in arterial thrombosis. Whether or not similar mechanisms are operative in the human cardiovascular system remains to be shown. However, LOX-1 is highly expressed in atherosclerotic human plaques 12 as well as within thrombi at the site of plaque rupture and coronary occlusion in patients with STsegment elevation myocardial infarction (unpublished observation of the investigators) suggesting that such mechanism may be operative in human ACS as well. Indeed, ACS patients display high oxLDL levels, regardless of total and LDL cholesterol values. 40 Preclinical studies in large animal models might be useful to appraise the efficacy and safety of specific LOX-1 inhibition in the setting of myocardial ischemia. Most interestingly, chronic LOX-1 inhibition in patients with hypercholesterolemia and/or low grade inflammation/oxidative stress may represent a further approach for primary prevention of ischemic complications, namely stroke and myocardial infarction. Besides, the novel finding that SIRT1 activated by LOX-1 and Oct-1 reduces thrombus formation may be of particular clinical interest as specific activators of the deacetylase are currently under development. 41 Taken together, our findings provide new insights into a dual role of the endothelial LOX-1 receptor in arterial thrombus formation further supporting the concept of low and high oxLDL concentration proposed previously; 42 indeed, we demonstrate that LOX-1 overexpression in the presence of physiological plasma levels of oxLDL triggers a protective pathway involving Oct-1 and SIRT1 and resulting in a reduced TF activity and prolonged thrombus formation ( Figure 7A) . In contrast, with elevated levels of oxLDL LOX-1 activates the prothrombotic ERK1/2 pathway LOX-1 overexpression and arterial thrombosis Figure 7 Schematic overview of LOX-1 signaling in arterial thrombus formation. (A) In the presence of normal ox LDL levels, the LOX-1 receptor modulates expression and activity of deacetylase SIRT1 through activation of transcription factor Oct-1. This subsequently inhibits expression of NFjB which leads to a repression of tissue factor expression and as a consequence to delayed thrombus formation. (B) In hyperlipidemia with elevated oxLDL levels, the Oct-1/SIRT1 protective pathway losses its activity and thus protective potential (right shadowed part of the scheme), while the redox-sensitive 'classical' LOX-1 pathway that involves MAPK and NFjB gets activated leading to enhanced tissue transcription and activity followed by increased thrombus formation.
